EMA Authorised: Pradaxa (dabigatran etexilate mesilate) — Boehringer Ingelheim International GmbH

View source ↗

Summary

EMA has authorised Pradaxa (dabigatran etexilate mesilate) for use in patients undergoing arthroplasty replacement and for prevention of venous thromboembolism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Pradaxa (dabigatran etexilate)

Snippet

Status: Authorised. Therapeutic area: Arthroplasty, Replacement;Venous Thromboembolism. MAH: Boehringer Ingelheim International GmbH. Decision date: 24/11/2025